Development of MRF for Characterization of Brain Tumors After Radiotherapy
Brain Tumor, Brain Necrosis, Brain Metastases
About this trial
This is an interventional diagnostic trial for Brain Tumor focused on measuring Magnetic Resonance Fingerprinting, Radiation necrosis
Eligibility Criteria
Inclusion Criteria for Healthy Participants: No history of cerebrovascular disease. No cognitive impairments. Able to provide informed consent. Inclusion Criteria for Participants with Brain Tumors: Biopsy-proven cases of developed recurrent tumor or radiation necrosis, OR: a. PET identified with developed recurrent tumor or radiation necrosis. OR b. Highly suspicious case with developed recurrent tumor or radiation necrosis confirmed by tumor board, attending physician or surgeon. ECOG performance status 0-2. Life expectancy > 6 months. Participant with other sites of extracranial metastatic disease or any prior or current systemic therapies will be considered and evaluated by the investigators of the study on a subject basis. Exclusion Criteria: Pregnant women OR lactating women Participants with ferromagnetic or otherwise non-MRI compatible aneurysm clips. Participants who cannot go into the MRI scanner due to metal implants and other medical conditions. The presence of an implanted medical device that is not MRI-compatible, including, but not limited to: pacemaker, defibrillator. Participants with contraindications for MRI due to embedded foreign metallic objects such as bullets, shrapnel, metalwork fragments, or other metallic material. Known history of severe claustrophobia. Participants unable to lay still in the scanner for 30 minutes at a time.
Sites / Locations
- Cleveland Clinic Taussig Cancer Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Healthy Volunteer Participants
Participants with Radiation Necrosis
Participants with Tumor Recurrence
Healthy volunteers will be recruited to evaluate the capability of MRF in conjunction with intravoxel incoherent motion (IVIM) MRI and serve as healthy control data to compare with the participant data.
The MRI scans (MRF and IVIM) will be performed on participants with newly developed necrosis prior to any further therapy implementation, surgical biopsy, or resection. For the participants undergoing surgical biopsy or resection after the MRI scans, the findings from the analysis of pathological biopsied specimen will serve as pathological confirmation for the MRI imaging findings
The MRI scans (MRF and IVIM) will be performed on participants with newly developed recurrent prior to any further therapy implementation, surgical biopsy, or resection. For the participants undergoing surgical biopsy or resection after the MRI scans, the findings from the analysis of pathological biopsied specimen will serve as pathological confirmation for the MRI imaging findings